Oxycodone: New 'old' drug

Current Opinion in Anaesthesiology

Volumn 22, Issue 4, 2009, Pages 459-462

  Olkkola, Klaus T ^a   Hagelberg, Nora M ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Analgesics; Opioid; Oxycodone

Indexed keywords

CYTOCHROME P450 3A; MORPHINE; OXYCODONE; OXYMORPHONE; QUINIDINE; RIFAMPICIN; ROPIVACAINE;

AREA UNDER THE CURVE; CANCER PAIN; CHRONIC PAIN; CLINICAL PHARMACOLOGY; CLINICAL STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; HUMAN; KIDNEY DISEASE; LIVER DISEASE; PATIENT CONTROLLED ANALGESIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; REVIEW; VISCERAL PAIN;

ANALGESICS, OPIOID; ANIMALS; DRUG INTERACTIONS; HUMANS; KIDNEY DISEASES; LIVER DISEASES; OXYCODONE;

EID: 68949113809     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e32832bc818     Document Type: Review

References (15)

1. Pöyhia R. Opioids in anaesthesia: a questionnaire survey in Finland. Eur J Anaesthesiol 1994; 11:101-110.
2. Lalovic B, Kharasch E, Hoffer C, et al. Pharmacokinetics and pharmaco-dynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 2006; 79:461-479.
3. Staahl C, Christrup LL, Andersen SD, etal. A comparative study of oxycodone and morphine in a multimodal, tissue-differentiated experimental pain model. Pain 2006; 123:28-36.
4. Kalso E. How different is oxycodone from morphine? Pain 2007; 132:227-228.
5. Nieminen T, Hagelberg NM, Saari TI, et al. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology (in press).
6. Liukas A, Kuusniemi K, Aantaa R, et al. Plasma concentrations of oral oxycodone are greatly increased in the elderly. Clin Pharmacol Ther 2008;84:462-467.
7. Tallgren M, Olkkola KT, Seppäla T, et al. Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. Clin Pharmacol Ther 1997; 61:655-661.
8. Kirvela M, Lindgren L, Seppäla T, Olkkola KT. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 1996; 8:13-18.
9. Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998; 64:603-611.
10. Lee HK, Lewis LD, Tsongalis GJ, et al. Negative urine opioid screening caused by rifampin-mediated induction of oxycodone hepatic metabolism. Clin Chim Acta2006; 367:196-200.
11. Hagelberg NM, Nieminen T, Saari TI, et al. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of oxycodone. Eur J Clin Pharmacol 2009; 65:263-271.
12. Silvasti M, Rosenberg P, SeppäläT, etal. Comparison of analgesic efficacy of oxycodone and morphine in postoperative intravenous patient-controlled analgesia. Acta Anaesthesiol Scand 1998; 42:576-580.
13. Hohwu L, Akre O, Bergenwald L, et al. Oral oxycodone hydrochloride versus epidural anaesthesia for pain control after radical retropubic prostatectomy. Scand J Urol Nephrol 2006; 40:192-197.
14. Mucci-LoRusso P, Berman BS, Silberstein PT, et al. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain 1998; 2:239-249.
15. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic noncancer pain: systematic review of efficacy and safety. Pain 2004; 112:372-380.